Nectar Lifesciences Q3 FY26: pharma business sold, buyback completed

Exceptional ItemResults RestatedPat NegativeResults View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹14.56

prior close

₹14.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.0% vs market

On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-2.0

15m

-3.4

30m

-5.1

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-3.8+0.1-4.0

Next day

-4.2+2.2-6.3

-5.4+1.8-7.1

-6.8+3.6-10.4

-4.3+2.3-6.6

-4.5+6.1-10.7

-5.9+6.4-12.4

15d

-9.8+7.0-16.8

-16.8+3.8-20.5

-32.8-5.2-27.6

-13.1+12.5-25.6

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 FY26 results. Pharma API and formulation businesses sold to Ceph Lifesciences for Rs 125,398.55 lakhs (completed Nov 10, 2025), yielding Rs 8,815.13 lakhs exceptional gain. Menthol assets also divested for Rs 2,000 lakhs. Capsule business sale for Rs 1,990 lakhs pending. Buyback of 3 crore shares at Rs 27 each (Rs 8,100 lakhs) completed Jan 13, 2026. Continuing ops show zero revenue; 9M FY26 PAT is Rs 22,496.68 lakh loss. Prior periods restated.

Likely market impact

Major restructuring: pharma business sold, buyback done, but 9M PAT shows Rs 22,497 lakh loss. Continuing ops have no revenue.